Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen.

Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R.

Mod Pathol. 2005 Feb;18(2):250-9.

2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
3.

Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.

Ciocca DR, Gago FE, Fanelli MA, Calderwood SK.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):32-40. Epub 2006 Oct 17. Review.

PMID:
17049840
4.

Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer.

Dirican E, Akkiprik M.

Tumour Biol. 2017 Mar;39(3):1010428317695529. doi: 10.1177/1010428317695529. Review.

PMID:
28351303
5.

The prognostic value of phosphatase and tensin homolog negativity in breast cancer: A systematic review and meta-analysis of 32 studies with 4393 patients.

Yang ZY, Yu YY, Yuan JQ, Shen WX, Zheng DY, Chen JZ, Mao C, Tang JL.

Crit Rev Oncol Hematol. 2016 May;101:40-9. doi: 10.1016/j.critrevonc.2016.01.013. Epub 2016 Jan 18. Review.

PMID:
26951995
6.

Tamoxifen resistance in breast cancer.

Chang M.

Biomol Ther (Seoul). 2012 May;20(3):256-67. doi: 10.4062/biomolther.2012.20.3.256. Review.

Supplemental Content

Support Center